🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the infection, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are seen in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization marks a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Testing Results and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which involves a dual-drug approach. The study involved nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in numerous developing nations.

Clinicians on the front lines have shared hope. Having a one-pill regimen of this kind is described as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea around the world.